Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fingolimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 11/20 | 1.00 |
| ▸ | S1PR3 known ✓ | Q99500 | 9/20 | 1.00 |
| ▸ | S1PR4 known ✓ | O95977 | 7/20 | 1.00 |
| ▸ | S1PR5 known ✓ | Q9H228 | 5/20 | 1.00 |
| ▸ | S1PR2 known ✓ | O95136 | 5/20 | 0.74 |
| ▸ | TNNC1 | P63316 | 6/20 | 1.00 |
| ▸ | SGPL1 | O95470 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | CERS2 | Q96G23 | 1/20 | 1.00 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.78 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.78 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391728 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL1372656 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3394554 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3389578 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3394797 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3390328 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL18904548 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3392313 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3393539 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| Hydrochloric Acid SCHEMBL8500527 | 0.98 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19336 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079927-A | Hypochlorous acid activation-based methylene blue-fingolimod prodrug, and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122080237-A | Preparation method of ovarian stem cells and application of ovarian stem cells in preparation of ovarian anti-aging drugs | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026103922-A1 | CHIMERIC SHUTTLING RECEPTOR | 深圳市湾岛细胞科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2026107075-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260142011-A1 | PHARMACOKINETIC MODELING SYSTEMS FOR IMPROVED THERAPEUTIC DOSING | PROMETHEUS LABORATORIES INC (US) | 2026-05-21 | — | — | US | claimed |
| US-6121329-A | Topical administration of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-09-19 | — | — | US | claimed |
| WO-2000041474-A2 | ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES THEREFOR | NOVARTIS AG (CH) | 2000-07-20 | — | — | WO | claimed |
| WO-2000027798-A1 | PRODUCTION OF 2-AMINO-2-[2-(4-C2-20-ALKYL-PHENYL)ETHYL]PROPANE-1,3-DIOLS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | claimed |
| EP-0990440-A1 | DRUG COMPOSITION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-04-05 | — | — | EP | claimed |
| EP-0941082-A2 | NEW USE FOR 1,3-PROPANEDIOL DERIVATIVES | Novartis AG (CH) | 1999-09-15 | — | — | EP | claimed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | claimed |
| WO-1998022100-A2 | NEW USE FOR 1,3-PROPANEDIOL DERIVATIVES | NOVARTIS AG (CH) | 1998-05-28 | — | — | WO | claimed |
| EP-0812588-A1 | EXTERNAL PREPARATION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-12-17 | — | — | EP | claimed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | claimed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | claimed |